InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(10), С. 36 - 41
Опубликована: Окт. 1, 2024
InFo Hämatologie + Onkologie, Год журнала: 2024, Номер 27(10), С. 36 - 41
Опубликована: Окт. 1, 2024
The Lancet, Год журнала: 2024, Номер 404(10454), С. 803 - 822
Опубликована: Авг. 1, 2024
Язык: Английский
Процитировано
60Lung, Год журнала: 2025, Номер 203(1)
Опубликована: Март 25, 2025
Lung cancer remains the leading cause of cancer-related mortality worldwide. Since 2024, non-small-cell lung (NSCLC) landscape has undergone a transformative shift, driven by 11 FDA approvals. Recent advances in molecular profiling, targeted therapies, and immunotherapies have revolutionized NSCLC management, ushering an era personalized treatment with improved patient outcomes. The increased adoption low-dose computed tomography (LDCT) for screening enhanced early detection, enabling intervention at more curable stages. Molecular diagnostics now play pivotal role guiding strategies, actionable genomic alterations (AGAs) informing use EGFR, ALK, ROS1, KRAS, NRG1, other inhibitors both advanced settings. For instance, therapies are increasingly being integrated into early-stage adjuvant osimertinib EGFR-mutated alectinib ALK-positive demonstrating substantial survival benefits. Immunotherapy, particularly immune checkpoint inhibitors, become cornerstone AGA-negative NSCLC, either as monotherapy or combination chemotherapy, is utilized perioperative setting. Furthermore, emerging such bispecific antibodies, antibody-drug conjugates (ADCs), novel immunotherapeutic agents show promise addressing resistance mechanisms improving outcomes advanced-stage disease. Although new challenges arise, evolving paradigm continues to prioritize precision medicine, offering hope prolonged quality life patients.
Язык: Английский
Процитировано
4Molecular Cancer, Год журнала: 2024, Номер 23(1)
Опубликована: Май 7, 2024
Abstract Background Recent evidence has demonstrated that abnormal expression and regulation of circular RNA (circRNAs) are involved in the occurrence development a variety tumors. The aim this study was to investigate effects circ_PPAPDC1A Osimertinib resistance NSCLC. Methods Human circRNAs microarray analysis conducted identify differentially expressed (DE) Osimertinib-acquired tissues effect on cell proliferation, invasion, migration, apoptosis assessed both vitro vivo. Dual-luciferase reporter assay, RT-qPCR, Western-blot, rescue assay were employed confirm interaction between circ_PPAPDC1A/miR-30a-3p/IGF1R axis. Results results revealed significantly upregulated acquired reduced sensitivity PC9 HCC827 cells promoted while inhibiting Osimertinib-resistant PC9/OR HCC829/OR cells, Silencing partially reversed resistance. Additionally, acted as competing endogenous (ceRNA) by targeting miR-30a-3p, Insulin-like Growth Factor 1 Receptor (IGF1R) identified functional gene for miR-30a-3p Furthermore, confirmed axis plays role activating PI3K/AKT/mTOR signaling pathway NSCLC with Conclusions Therefore, first time we exerts an oncogenic sponging active IGF1R/PI3K/AKT/mTOR pathway. may serve novel diagnostic biomarker therapeutic target patients Graphical
Язык: Английский
Процитировано
10Journal of Molecular Biology, Год журнала: 2025, Номер unknown, С. 169050 - 169050
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
2International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2042 - 2042
Опубликована: Фев. 26, 2025
The development of tyrosine kinase inhibitors (TKIs) for late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) represented a drastic change in the treatment cancer. Drug resistance develops after certain period first-line TKI treatment, which has led to decades changing guidelines EGFR-mutant NSCLC. This study discussed potential mechanisms drug against and successive strategies. Next-generation sequencing (NGS) may play role evaluation treatment. Emerging combination regimens ongoing trials were discussed. Potential future strategies management proposed this study.
Язык: Английский
Процитировано
2International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 2350 - 2350
Опубликована: Март 6, 2025
Non-small cell lung cancer (NSCLC) is a challenging disease, with the epidermal growth factor receptor (EGFR) being key target for new, effective treatments crucial signaling pathways regulating survival. Targeting EGFR-mediated offers promising strategies to improve NSCLC therapies, particularly in overcoming resistance EGFR-mutant cancer. In this study, we investigated anticancer effects of panduratin A, naturally occurring flavonoid from Boesenbergia rotunda, on human lines expressing both wild-type EGFR (A549) and mutant (H1975) using vitro experiments molecular docking approaches. Cytotoxicity screening revealed that A exhibits potent A549 (IC50 6.03 ± 0.21 µg/mL) H1975 5.58 0.15 while demonstrating low toxicity normal MRC5 cells (12.96 0.36 µg/mL). Furthermore, western blotting flow cytometric analyses indicated induces apoptosis by inhibiting p-EGFR its downstream effectors, p-STAT3 p-Akt, cells. Additionally, study showed lower binding energy between proteins, comparable tyrosine kinase inhibitors (EGFR TKIs). The ADMET prediction also highlighted A's exceptional drug-like properties. This concludes shows significant promise as an anti-lung candidate NSCLC, offering economical strategy.
Язык: Английский
Процитировано
2Annals of Oncology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
9Cancer Treatment Reviews, Год журнала: 2025, Номер 134, С. 102902 - 102902
Опубликована: Фев. 16, 2025
Язык: Английский
Процитировано
1Materials Today Bio, Год журнала: 2025, Номер 31, С. 101616 - 101616
Опубликована: Фев. 26, 2025
Язык: Английский
Процитировано
1International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3264 - 3264
Опубликована: Апрель 1, 2025
In the tumor context, platelets play a significant role in primary progression, dissemination and metastasis. Analysis of this interaction various cancers, such as non-small cell lung cancer (NSCLC), demonstrate that can both transfer receive biomolecules (e.g. RNA proteins) to from at different stages, becoming tumor-educated platelets. To investigate how are able oncogenic material, we developed vitro platelet-like particles (PLPs), differentiated MEG-01 line, stably carry protein KRASG12D oncogene fusion with GFP. We co-cultured these PLPs NSCLC H1975 cells assess their ability material. observed generated were capable expressing transferring its forms using qPCR imaging techniques. Additionally, found coculturing loaded GFP-KRASG12D increased proliferative capacity specific PLP concentrations. conclusion, our study successfully engineered an line produce carrying simulating microenvironment, demonstrating efficient impact on enhancing proliferation.
Язык: Английский
Процитировано
1